Study Evaluating the Safety and Tolerability of L-377202
Status:
Completed
Trial end date:
2001-11-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to (1) determine the maximally tolerated dose (MTD) of
L-377202 administered once every 3 weeks, (2) evaluate the safety and tolerability of
L-377202 including the dose-limiting adverse effects of treatment with L-377202, and (3)
assess the pharmacokinetics of various doses of L-377202 and the plasma profile of liberated
doxorubicin and leu-doxorubicin.